Sophia Genetics (SOPH) - Bathi resik saben saham (EPS TTM)

While strategic alliances with pharma behemoths expand the presence of SOPHiA GENETICS SA (SOPH) in clinics, internal growth is driven by the implementation of AI analytics and the influx of SaaS revenues. Fundamental TTM earnings per share visualize this momentum, where the -1.09 mark reflects the current state of profitability. However, success relies on global genetic testing rates and strict compliance with data privacy regulations.

The SOPHiA GENETICS SA (SOPH) cloud AI platform for clinical genomics monetizes a unique patient dataset and deep integration into hospital networks. By analyzing the rolling annual earnings per share on GURU.Markets, an investor can see the actual equity return of a single security, where a steady upward trend confirms the capitalization of a technological advantage, while a sharp impulse at the peak signals the risk of overpaying for the asset.